Exact Mass: 1128.424501
Exact Mass Matches: 1128.424501
Found 20 metabolites which its exact mass value is equals to given mass value 1128.424501,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PIP3(18:2(9Z,12Z)/20:1(11Z))
C47H88O22P4 (1128.4717468000001)
PIP3(18:2(9Z,12Z)/20:1(11Z)) is a phosphatidylinositol trisphosphate. Phosphatidylinositol trisphosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a trisphosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol trisphosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositols trisphosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 18 and 20 carbons are the most common. PIP3(18:2(9Z,12Z)/20:1(11Z)), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of eicosenoic acid at the C-2 position. The linoleic acid moiety is derived from seed oils, while the eicosenoic acid moiety is derived from vegetable oils and cod oils. The most important phosphatidylinositol trisphosphate in both quantitative and biological terms is phosphatidylinositol 3,4,5-triphosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signalling molecules, via the action of phospholipase C enzymes. Phosphatidylinositols phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol. [HMDB] PIP3(18:2(9Z,12Z)/20:1(11Z)) is a phosphatidylinositol trisphosphate. Phosphatidylinositol trisphosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a trisphosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol trisphosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositols trisphosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 18 and 20 carbons are the most common. PIP3(18:2(9Z,12Z)/20:1(11Z)), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of eicosenoic acid at the C-2 position. The linoleic acid moiety is derived from seed oils, while the eicosenoic acid moiety is derived from vegetable oils and cod oils. The most important phosphatidylinositol trisphosphate in both quantitative and biological terms is phosphatidylinositol 3,4,5-triphosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signalling molecules, via the action of phospholipase C enzymes. Phosphatidylinositols phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.
Epioritin-(4??鈥樏傗垎6)-epioritin-(4??鈥樏傗垎6)-epioritin-4??-ol nona-O-methylether tetra-acetate
26-O-beta-D-glucopyranosyl 22-hydroxyfurost-5,25(27)-dien-1beta,3beta,26-triol 1-O-alpha-L-rhamnopyranosyl(1->2)-4-O-sulfo-alpha-L-arabinopyranosido-3-O-beta-D-glucopyranoside
PIP3(38:3)
C47H88O22P4 (1128.4717468000001)
Desmopressin Acetate
C48H68N14O14S2 (1128.4480628000001)
D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents > D014667 - Vasopressins D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones D006401 - Hematologic Agents > D003029 - Coagulants > D006490 - Hemostatics D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D045283 - Natriuretic Agents > D050034 - Antidiuretic Agents
{4-hydroxy-6-[(6-hydroxy-7,9,13-trimethyl-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-[3-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-14-yl)oxy]-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-3-yl}oxidanesulfonic acid
(2s)-n-[(3r,4r,13s,20r,21as)-16-[(2s)-butan-2-yl]-5,8,11,14-tetrahydroxy-3-methyl-10-{[(2r)-2-nitrocyclopropyl]methyl}-1,17-dioxo-7,13-bis[(1r)-1-phenylethyl]-20-[(1z)-prop-1-en-1-yl]-3h,4h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-c]1-oxa-4,7,10,13,16-pentaazacyclononadecan-4-yl]-2-[(5-chloro-1-hydroxypyrrol-2-yl)formamido]-3-[(2r)-2-nitrocyclopropyl]propanimidic acid
C55H69ClN10O14 (1128.4683003999999)
4-(methoxycarbonyl)-7-methyl-1-{[3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl]oxy}-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-6-yl 4-(2,2-dimethoxyethyl)-5-ethenyl-6-{[3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate
(2s)-n-[(3r,4r,7s,10r,13s,16s,20r,21as)-16-[(2s)-butan-2-yl]-5,8,11,14-tetrahydroxy-3-methyl-10-{[(1r,2r)-2-nitrocyclopropyl]methyl}-1,17-dioxo-7,13-bis[(1r)-1-phenylethyl]-20-[(1z)-prop-1-en-1-yl]-3h,4h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-c]1-oxa-4,7,10,13,16-pentaazacyclononadecan-4-yl]-2-[(5-chloro-1-hydroxypyrrol-2-yl)formamido]-3-[(1r,2r)-2-nitrocyclopropyl]propanimidic acid
C55H69ClN10O14 (1128.4683003999999)
2-[(5-chloro-1-hydroxypyrrol-2-yl)formamido]-3-(2-nitrocyclopropyl)-n-{5,8,11,14-tetrahydroxy-3-methyl-10-[(2-nitrocyclopropyl)methyl]-1,17-dioxo-7,13-bis(1-phenylethyl)-20-(prop-1-en-1-yl)-16-(sec-butyl)-3h,4h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-c]1-oxa-4,7,10,13,16-pentaazacyclononadecan-4-yl}propanimidic acid
C55H69ClN10O14 (1128.4683003999999)
n-(6,19-dihydroxy-20-{[hydroxy(quinoxalin-2-yl)methylidene]amino}-2,4,12,15,17,25-hexamethyl-11,24-bis(2-methylpropyl)-27-(methylsulfanyl)-3,10,13,16,23,26-hexaoxo-9,22-dioxa-28-thia-2,5,12,15,18,25-hexaazabicyclo[12.12.3]nonacosa-5,18-dien-7-yl)quinoxaline-2-carboximidic acid
C53H68N12O12S2 (1128.4520848000002)
[(3s,4r,5r,6s)-4-hydroxy-6-{[(1s,2s,4s,6s,7s,8r,9s,12s,13r,14r,16r)-6-hydroxy-7,9,13-trimethyl-16-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-[3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-14-yl]oxy}-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl]oxidanesulfonic acid
(1s,4as,6s,7r,7as)-4-(methoxycarbonyl)-7-methyl-1-{[(2s,3r,4s,5r,6r)-3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl]oxy}-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-6-yl (4s,5r,6s)-4-(2,2-dimethoxyethyl)-5-ethenyl-6-{[(2s,3r,4s,5r,6r)-3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate
n-(6,19-dihydroxy-20-{[hydroxy(quinoxalin-2-yl)methylidene]amino}-2,4,12,15,17,25-hexamethyl-27-(methylsulfanyl)-3,10,13,16,23,26-hexaoxo-11,24-bis(sec-butyl)-9,22-dioxa-28-thia-2,5,12,15,18,25-hexaazabicyclo[12.12.3]nonacosa-5,18-dien-7-yl)quinoxaline-2-carboximidic acid
C53H68N12O12S2 (1128.4520848000002)